An observational study in Crohn Disease and Plaque Psoriasis, sponsored by Celltrion HealthCare France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Celltrion HealthCare France (part of Celltrion) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Crohn Disease with a site in France — 80 open to participants now, 104 under way, 29 of them phase 3. Crohn Disease · France.
Among the 316 studies in Crohn Disease with a site in France, this one is the 46th largest by planned enrollment of the 87 observational ones that give a count, is one of 27 that started in 2025, is one of 88 observational ones, reaches primary completion later than 54 of the 103 other live ones, and was the 293rd registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →80 of the 316 studies in Crohn Disease with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 27 more countries
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 64 · Phase 3 86 · Phase 4 16
First in 1990; this study’s year is marked. 27 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 225 is above the median of 185 across 645 observational studies indexed under Crohn Disease.
Median enrollment 147 across the 228 interventional studies, 240 across the 87 observational. Of the 194 that completed or were terminated, 78 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
150 of 316 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celltrion HealthCare France, one of the names counted as Celltrion. Under that name alone:
Celltrion HealthCare France is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Celltrion has 6 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Crohn Disease with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04777656Phase 3Assistance Publique - Hôpitaux de ParisUse of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. | 2026-11 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 32 to your calendar (.ics) → With an account.
Among the 316 studies in Crohn Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided, independently of the study and as part of a shared medical decision, to switch them to STEQEYMA®. The main aim of this study is to the maintenance of clinical remission 12 months after initiation of a biosimilar as well as patient satisfaction 6 and 12 months after initiation of a biosimilar.
Biotherapies have revolutionized the management of chronic inflammatory diseases in gastroenterology (Crohn's disease and ulcerative colitis), dermatology (e.g. plaque psoriasis and chronic spontaneous urticaria). However, due to their specificity and complexity, these treatments have a high financial cost, which has a significant impact on healthcare systems.
Following the loss of patent protection for these reference biotherapies, biosimilars were developed. These are similar to the reference molecules, but not strictly identical. As a result, to obtain marketing authorization, a biosimilar must demonstrate equivalence to the reference biologic in terms of efficacy and safety in a single indication defined in a Phase I (pharmacokinetic) and Phase III (clinical) study, before being extrapolated to other indications, as applicable.
This study aims to address these subjects for STEQEYMA® (CT-P43), a biosimilar ustekinumab approved by the European Commission on August 22, 2024, through a centralized procedure. STEQEYMA® is indicated for the treatment of moderate to severe forms of Crohn's disease (CD) and plaque psoriasis.
ROLL'YN-UST (CohoRt for the management Of chronic infLammatory diseases in a nationaL observational studY, in patieNts treated by Steqeyma®, an USTekinumab biosimilar - Etude observationnelle de cohorte pour la prise en charge des patients atteints de pathologies inflammatoires chroniques traités par Steqeyma®, un biosimilaire de l'ustekinumab) is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided, independently of the study and as part of a shared medical decision, to switch them to STEQEYMA®. The main aim of this study is to the maintenance of clinical remission 12 months after initiation of a biosimilar as well as patient satisfaction 6 and 12 months after initiation of a biosimilar.
Adult dermatology or gastroenterology patients presenting a diagnosis for any of the following pathologies:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Switch from ustekinumab originator in patients with Crohn's disease
Drug: Ustekinumab 45 mg · Drug: Ustekinumab 90 mg
Switch from ustekinumab originator in patients with Plaque Psoriasis
Drug: Ustekinumab 45 mg · Drug: Ustekinumab 90 mg
biosimilar
biosimilar
Maintenance of remission, 12 months after initiation of biosimilar treatment
Percentage of patients still in clinical remission 12 months after initiation of biosimilar treatment according to the definitions used in the inclusion criteria.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Sep 2027, 30 months after the start.
Of 73 industry-sponsored observational studies under Crohn Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's planned 30 months is below that.
Counting every sponsor, half of 304 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.